Obrindatamab, a humanized anti-B7-H3/CD3 bispecific antibody, targets B7-H3 and CD3, facilitating redirected cytotoxic T-lymphocyte (CTL) activity towards B7-H3-expressing cancer cells. It is utilized in cancer research [1].
CAS Number:
[2069959-72-2]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted